跳至主要内容
临床试验/NCT03520140
NCT03520140已完成不适用

Prevalence of Familial Hypercholesterolaemia (FH) in Italian Patients With Coronary Artery Disease

Heart Care Foundation81 个研究点 分布在 1 个国家目标入组 5,415 人开始时间: 2016年6月15日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
5,415
试验地点
81
主要终点
Genetic examination

研究概览

简要总结

Evaluate the prevalence of familial hypercholesterolemia (FH) in patients with documented coronary artery disease (CAD) event [acute myocardial infarction (AMI), acute coronary syndrome (ACS), coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI)] followed by 100 cardiological centers representative of the whole Italian territory

详细描述

Familial hypercholesterolemia (FH) is a disease that causes exposure to elevated plasma levels of LDL cholesterol (LDL-C, low-density lipoprotein) and increasing the risk of premature coronary heart disease (coronary artery disease, CAD). The FH is a co-dominant genetic disease and can occur in heterozygous and homozygous form, with different severity. The prevalence in whites is estimated to be 1.500 for heterozygous familial hypercholesterolemia (HeFH) and 1.1000000 for homozygous familial hypercholesterolemia (HoFH). This prevalence is probably an underestimate, as it is based on prevalence rates in in-patient and disease registries, and is influenced by the early mortality of patients with FH. The situation does not improve if we consider patients admitted for acute coronary event (myocardial infarction - AMI and / or unstable angina, - ACS). If we consider LDL cholesterol cumulative load in a person affected by FH, the best approach intervention to reduce cardiovascular mortality is an early diagnosis and treatment.

The primary aim of the study is to evaluate the prevalence of FH in patients with documented CAD event (AMI, ACS, CABG or PCI) followed by 100 cardiologic centers representative of the whole Italian territory. The results will also permit to increase the cardiologists awareness of FH. Secondary objective will be the validation of Dutch Lipid Clinic Network (DLCN) criteria (annex 1), in the Italian CAD population (12). The characterization of the patients, carried out during the study, will allow to identify the priorities for health inteventions aimed at improving the FH diagnosis in the general population through the a cascade screening in the relatives of the genetically characterized subjects.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients must have a documented coronary artery disease, more precisely:
  • ACS PCI CABG The index event must be occurred between 15 days and 8 weeks preceding the enrollment.
  • Written informed consent to participate to the study

排除标准

  • Patients unwilling to give their written informed consent.

结局指标

主要结局

Genetic examination

时间窗: Inclusion

Sequencing of (LDLR, APOB, PVSK9 and LDLRAP1)

Familial hypercholesterolemia diagnosis

时间窗: Inclusion

Dutch Lipid Clinic Network Score (DLCNS) for FH The DLCNS is a validated set of criteria based on the patients family history of premature cardiovascular disease (CVD) in their first degree relatives, their own CVD history, their untreated lipid levels and physical signs such as the presence of tendon xanthomata or arcus cornealis prior to the age of 45. The subsequent score categorizes patients by the likelihood of Familial Hypercholesterolaemia (FH) diagnosis. Definite FH if score \>8 Probable FH if score 6-8 Possible FH if score 3-5 Unlikely FH if score \<3

次要结局

未报告次要终点

研究者

发起方
Heart Care Foundation
申办方类型
Other
责任方
Sponsor

研究点 (81)

Loading locations...

相似试验

Prevalence of Familial Hypercholesterolaemia (FH) in... | 临床试验